J&J Medical Connect
INVEGA TRINZA®

(paliperidone palmitate)

J&J Medical Connect

Connect with us

  • Products

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

Conversion From Another Antipsychotic to INVEGA TRINZA

Last Updated: 11/16/2026

Summary

  • INVEGA TRINZA is to be used only after the patient has been adequately treated with INVEGA SUSTENNA for at least 4 months. The last 2 doses of INVEGA SUSTENNA immediately before transition to INVEGA TRINZA should be the same.1
  • Due to the slow release characteristics of INVEGA TRINZA, the product is not intended to be used for initiation of treatment in acutely symptomatic patients or in patients who are immediately transitioning from oral to long-acting injectable (LAI) antipsychotic therapy. Rather, INVEGA TRINZA is intended to be used in patients who have already demonstrated a therapeutic effect and ability to tolerate INVEGA SUSTENNA over a treatment period of at least 4 months at the time of initiation of INVEGA TRINZA.1
  • A prospective, observational study evaluated the maintenance of clinical efficacy and tolerability, and variation of paliperidone plasma levels during the transition from INVEGA SUSTENNA to INVEGA TRINZA. After a slight initial increase, plasma levels were stabilized after the fourth administration of INVEGA SUSTENNA, and a slight reduction in plasma levels (not statistically significant) was observed during treatment with INVEGA TRINZA.2
  • A multicenter, retrospective, observational study evaluated the effectiveness of INVEGA TRINZA among patients with schizophrenia who transitioned from INVEGA SUSTENNA to INVEGA TRINZA. INVEGA TRINZA treatment was initiated at the doses of 546 mg and 819 mg in 36.5% and 39.9% of patients, respectively. Majority of patients (90.8%) were transitioned from INVEGA SUSTENNA to INVEGA TRINZA at the conversion ratio of 3.5.3
  • A multicenter, open-label, interventional study evaluated the efficacy and safety of adults with schizophrenia transitioning from oral antipsychotics to INVEGA SUSTENNA followed by INVEGA TRINZA. Significant improvements in Clinical Global Impression-Severity of Schizophrenia (CGI-SS) scores were observed across the 66-week follow-up (mean change [SD], -1.4 [0.69]; 95% CI, -1.50 to -1.22; P<0.001), with no new safety concerns identified.4
  • In a real-world observational study, conversion from INVEGA SUSTENNA to INVEGA TRINZA was not associated with an increased overall side effect burden, and the adverse event profile remained generally stable following conversion.5
  • A double-blind (DB), placebo (PBO)-controlled, relapse-prevention study evaluated the efficacy and safety of INVEGA TRINZA-enrolled schizophrenia patients who were previously treated with oral antipsychotics and had acute symptoms or previously treated with LAI antipsychotic therapy and were clinically stable. An open-label (OL) phase preceded the DB phase, in which patients were stabilized with INVEGA SUSTENNA over 4 months before they received a dose of INVEGA TRINZA. Table: Dosing Details for Patients Converting From Previous Antipsychotics in a Clinical Trial describes how patients converted to INVEGA TRINZA from their previous antipsychotic regimen.6
    • For patients who had never taken oral paliperidone or oral or injectable risperidone, tolerability with oral paliperidone or oral risperidone prior to initiating treatment with INVEGA SUSTENNA was confirmed.

DOSAGE STRENGTH INFORMATION

Doses of paliperidone palmitate extended-release injectable suspension may be expressed in milligram equivalents of paliperidone (active moiety) or milligrams of paliperidone palmitate. Dosage information in this response has been converted to mg of paliperidone palmitate to reflect the commercially available INVEGA SUSTENNA and INVEGA TRINZA dosage strengths in the United States. The conversion factor from mg eq. to mg is 1.56.

  • INVEGA SUSTENNA doses expressed as 39, 78, 117, 156, and 234 mg of paliperidone palmitate are equal to 25, 50, 75, 100, and 150 mg eq. of paliperidone, respectively.INVEGA TRINZA doses expressed as 273, 410, 546, and 819 mg of paliperidone palmitate are equal to 175, 263, 350, and 525 mg eq. of paliperidone, respectively.

CLINICAL STUDIES

Mauri et al (2022)2 conducted a prospective, observational study to evaluate the maintenance of clinical efficacy and tolerability, and variation of paliperidone plasma levels during the transition from INVEGA SUSTENNA to INVEGA TRINZA.

Study Design/Methods

  • Patients aged 18-66 years with schizophrenia were included, and observation was ongoing at the time of reporting.
  • Clinical assessments were performed at the time of the first INVEGA SUSTENNA administration and then every 28 days up to the time of switching to INVEGA TRINZA, followed by 28 days and 2 months after the first INVEGA TRINZA administration and then every 3 months until 9 months of the first INVEGA TRINZA administration.
  • All patients were stabilized on INVEGA SUSTENNA for 4 months and then switched to INVEGA TRINZA.

Results

  • Overall, 22 patients were included (mean age, 46.91 years) in the study.
  • The mean (standard deviation [SD]) plasma level of paliperidone was 32.84 (15.21) ng/mL at the time of transitioning from INVEGA SUSTENNA to INVEGA TRINZA and 23.56 (11.98) ng/mL 28 days after first INVEGA TRINZA administration.
  • The plasma levels varied from a minimum of 16.40 ng/mL to a maximum of 30.22 ng/mL for INVEGA SUSTENNA, and from a minimum of 19.09 ng/mL to a maximum of 35.01 ng/mL for INVEGA TRINZA.
  • After a slight initial increase, plasma levels were stabilized after the fourth administration of INVEGA SUSTENNA, and a slight reduction in plasma levels (not statistically significant) was observed during treatment with INVEGA TRINZA.
    • After steady-state paliperidone concentrations were achieved with INVEGA SUSTENNA treatment, the stability of plasma concentration of paliperidone was maintained during the transition to INVEGA TRINZA without oral supplementation of paliperidone.
  • From the first study dose of INVEGA SUSTENNA to 9 months on treatment with INVEGA TRINZA, statistically significant improvements in Brief Psychiatric Rating Scale (BPRS) total scores (P=0.006), Positive and Negative Symptom Scale (PANSS) scores (P=0.0016), and Hamilton Rating Scale of Depression (HAM-D) scores (P=0.003) were observed.

Corbeil et al (2022)3 conducted a multicenter, retrospective, observational study to evaluate the effectiveness of INVEGA TRINZA among patients with schizophrenia who transitioned from INVEGA SUSTENNA to INVEGA TRINZA.

Study Design/Methods

  • Patients aged ≥18 years with a diagnosis of schizophrenia spectrum psychotic disorder based on the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) classification who received ≥1 dose of INVEGA TRINZA during observation period were included.
  • The primary outcome measured was relapse, which was defined as an increase of psychotic symptoms requiring either:
    • Discontinuation of INVEGA TRINZA in favor of another antipsychotic
    • Increasing INVEGA TRINZA dose or reducing the dosing interval by >2 weeks
    • Use of supplemental oral antipsychotic due to psychotic symptoms
    • Psychiatric hospitalization

Results

  • A total of 178 patients were included (mean age, 33.9 years) in the study.
    • In the 2 years prior to INVEGA TRINZA initiation, 50.6% of patients had been hospitalized at least once for psychiatric reasons, and the mean Clinical Global Impression – Severity (CGI-S) score was 3.1 at INVEGA TRINZA initiation.
  • Patients received INVEGA SUSTENNA for an average of 2.4 years before being initiated on INVEGA TRINZA.
    • The last administered dose of INVEGA SUSTENNA was 156 mg and 234 mg in 35.6% and 35.1% of patients, respectively.
    • INVEGA TRINZA treatment was initiated at the doses of 546 mg and 819 mg in 36.5% and 39.9% of patients, respectively.
    • Majority of patients (90.8%) were transitioned from INVEGA SUSTENNA to INVEGA TRINZA at the conversion ratio of 3.5.
  • At 12 months after transitioning to INVEGA TRINZA, 33 patients had a relapse, and 19 patients discontinued treatment with INVEGA TRINZA.
  • At 12 months, the relapse-free survival probability was 0.788 (95% confidence interval [CI], 0.725-0.856), discontinuation-free survival probability was 0.863 (95% CI, 0.806-0.924), and hospitalization-free survival probability was 0.889 (95% CI, 0.840-0.940).
  • The most common reasons for treatment discontinuation were side effects (n=7), insufficient response (n=4), patient’s decision (n=3), relapse (n=1), and other consideration (n=4).

Bizoza et al (2026)4 conducted a multicenter, open-label, interventional study to evaluate the efficacy and safety of adults with schizophrenia transitioning from oral antipsychotics to INVEGA SUSTENNA, followed by INVEGA TRINZA, in routine Rwandan healthcare settings.

Study Design/Methods

  • The study enrolled 93 adults aged 18-35 years with schizophrenia across 5 Rwandan centers.
  • Patients received standard-of-care oral antipsychotics during a 24-week observation phase and oral risperidone during a 3-day run-in phase (observation/run-in [OR] phase). Patients then received INVEGA SUSTENNA for ≥17 weeks before transitioning to INVEGA TRINZA for 24 weeks (lead-in/maintenance [LM] phase).
  • The primary endpoint was the change in CGI-SS score from baseline to week 66. Secondary endpoints included changes in CGI-SS and Personal and Social Performance (PSP) scores in both OR and LM phases, as well as safety outcomes.

Results

  • Overall, 86/93 (92.5%) completed the 66-week study.
  • Across the 66-week follow-up period, CGI-SS scores improved significantly (mean change [SD], -1.4 [0.69]; 95% CI, -1.50 to -1.22; P<0.001).
    • Clinically meaningful improvements in CGI-SS scores were not observed in the OR phase; however, were observed during the LM phase (mean change [SD], -1.2 [0.67]; 95% CI, -1.28 to -1.10; P<0.001).
  • PSP scores improved significantly during the LM phase (mean change [SD], +17.1 [13.62]; 95% CI, 14.29-19.93; P<0.001) and across the overall follow-up period (mean change [SD], +17.6 [11.13]; 95% CI, 15.25-19.86; P<0.001).
  • Overall, 75% of patients experienced ≥1 treatment-emergent adverse event, most of which were mild to moderate in severity, and no new safety concerns were identified.

Kuru et al (2026)5 conducted a real-world, observational, within-patient study evaluating tolerability following conversion from INVEGA SUSTENNA to INVEGA TRINZA in patients with schizophrenia.

Results

  • Of the 67 patients who initiated INVEGA SUSTENNA, 43 patients who were stabilized and transitioned to INVEGA TRINZA were included in the final analysis.
  • Overall side effect profiles were similar before and after conversion to INVEGA TRINZA, with no increase in the overall UKU side effect burden.
  • The frequency of adverse effects remained generally stable following conversion; however, constipation decreased significantly after switching to INVEGA TRINZA (P=0.016).
  • No new safety signals were identified following conversion to INVEGA TRINZA.

Berwaerts et al (2015)6 conducted a DB, PBO-controlled, relapse-prevention study to evaluate the efficacy and safety of INVEGA TRINZA in delaying time-to-relapse of schizophrenia symptoms in patients previously treated with INVEGA SUSTENNA for at least 4 months. The study included 4 phases: a screening and oral tolerability testing phase of up to 3 weeks, a 17-week OL transition phase, a 12-week OL maintenance phase, and a DB phase of variable length.

  • During the transition phase, all patients received 4 months of INVEGA SUSTENNA treatment.
  • During the maintenance phase, patients received a single dose of INVEGA TRINZA (273, 410, 546, or 819 mg; a 3.5-fold multiple of the final INVEGA SUSTENNA dose administered) in either the deltoid or gluteal muscle.
  • During the DB phase, stabilized patients were randomized 1:1 to receive a fixed dose of INVEGA TRINZA (the same dose as during the maintenance phase) or PBO.
  • Table: Dosing Details for Patients Converting From Previous Antipsychotics in a Clinical Trial describes how patients converted to INVEGA TRINZA from their previous antipsychotic regimen.

Dosing Details for Patients Converting From Previous Antipsychotics in a Clinical Trial6,7
Transition From:
OL Transition Phase (17 Weeks)
OL Maintenance Phase (12 Weeks)
DB Phase (Variable)
 
Day 1 (deltoid injection)
Day 8
(deltoid injection, unless where indicated)

Day 36
(deltoid or gluteal injection)

Day 64
(deltoid or gluteal injection)

Day 92
(deltoid or gluteal injection)

Day 120
(deltoid or gluteal injection)

Day 204 and every 12 weeks
(deltoid or gluteal injection)

Oral APS6
INVEGA SUSTENNA 234 mg
INVEGA SUSTENNA 156 mg
Flexible-dose INVEGA SUSTENNA 78, 117, 156, or 234 mg
Flexible-dose INVEGA SUSTENNA 78, 117, 156, or 234 mg
Same INVEGA SUSTENNA dose as on Day 64
INVEGA TRINZA dose (3.5-fold multiple of final INVEGA SUSTENNA dose)
Same INVEGA TRINZA dose as on Day 120
INVEGA SUSTENNA7
NA
INVEGA SUSTENNA dose unchanged from previous (deltoid or gluteal)
Flexible-dose INVEGA SUSTENNA 78, 117, 156, or 234 mg
Flexible-dose INVEGA SUSTENNA 78, 117, 156, or 234 mg
Same INVEGA SUSTENNA dose as on Day 64
INVEGA TRINZA dose (3.5-fold multiple of final INVEGA SUSTENNA dose)
Same INVEGA TRINZA dose as on Day 120
RLAI7
NA
RLAI 25 mg, 37.5 mg, or 50 mg switched to INVEGA SUSTENNA 78 mg, 117 mg, or 156 mg, respectively
Flexible-dose INVEGA SUSTENNA 78, 117, 156, or 234 mg
Flexible-dose INVEGA SUSTENNA 78, 117, 156, or 234 mg
Same INVEGA SUSTENNA dose as on Day 64
INVEGA TRINZA dose (3.5-fold multiple of final INVEGA SUSTENNA dose)
Same INVEGA TRINZA dose as on Day 120
Other LAIsa
NA
INVEGA SUSTENNA 234 mg
Flexible-dose INVEGA SUSTENNA 78, 117, 156, or 234 mg
Flexible-dose INVEGA SUSTENNA 78, 117, 156, or 234 mg
Same INVEGA SUSTENNA dose as on Day 64
INVEGA TRINZA dose (3.5-fold multiple of final INVEGA SUSTENNA dose)
Same INVEGA TRINZA dose as on Day 120
aOther LAIs included haloperidol decanoate, zuclopenthixol decanoate, and fluphenazine decanoate.6
Abbreviations: APS, antipsychotics; DB, double-blind; LAIs, long-acting injectables; NA, not applicable; OL, open-label; RLAI, risperidone long-acting injection.

CASE REPORT

Cellini et al (2021)8 evaluated variations in plasma concentrations and clinical outcomes and possible relapses in 5 clinically stable patients with schizophrenia or schizoaffective disorder who switched from INVEGA SUSTENNA to INVEGA TRINZA. Overall, 5 patients, including 4 with schizophrenia (age range, 42-83 years) and 1 with schizoaffective disorder (age, 51 years), were enrolled. No major comorbidities were present (except patient 4, who had type 2 diabetes mellitus), and no significant concomitant medications were administered (except diazepam ≤10 mg at bedtime or equivalent). All patients received INVEGA SUSTENNA for ≥9 months (except patient 1, who had received INVEGA SUSTENNA for 4 months), and all (except patients 3 and 5) were switched to a 3.5-fold dose of INVEGA TRINZA administered on day 0 and at months 3, 6, and 9. Paliperidone plasma levels, PANSS scores, and Global Assessment of Functioning (GAF) scores were monitored before each scheduled administration of INVEGA TRINZA.

In 3 patients, the baseline steady-state plasma concentration of paliperidone was within the therapeutic range (20-60 ng/mL) during INVEGA SUSTENNA maintenance. In patients 2, 4, and 5, the plasma concentrations were within the therapeutic range at baseline and reduced to subtherapeutic levels at month 3 after switching to INVEGA TRINZA. Patients 1 and 3 had subtherapeutic plasma concentrations of paliperidone at baseline, which remained stable throughout the follow-up period.

No relapse was reported throughout the follow-up period. In patients 2, 4, and 5, no strong relationship was established between the reduced plasma concentrations and clinical outcomes. The PANSS scores remained stable, and the GAF scores did not show significant worsening.

LITERATURE SEARCH

A literature search of MEDLINE®, Embase®, BIOSIS Previews®, and Derwent Drug File (and/or other resources, including internal/external databases) pertaining to this topic was conducted on 21 October 2026.

 

References

1 Gopal S, Vermeulen A, Nandy P, et al. Practical guidance for dosing and switching from paliperidone palmitate 1 monthly to 3 monthly formulation in schizophrenia. Curr Med Res Opin. 2015;31(11):2043-2054.  
2 Mauri MC, Franco G, Minutillo A, et al. The switch from paliperidone long-acting injectable 1- to 3-monthly: clinical pharmacokinetic evaluation in patients with schizophrenia (preliminary data). J Clin Psychopharmacol. 2022;42(1):23-30.  
3 Corbeil O, Essiambre AM, Béchard L, et al. Real-life effectiveness of transitioning from paliperidone palmitate 1-monthly to paliperidone palmitate 3-monthly long-acting injectable formulation. Ther Adv Psychopharmacol. 2022;12:20451253221136021.  
4 Bizoza R, Mehawej J, Musoni-Rwililiza E, et al. Efficacy and safety of long-acting injectable paliperidone palmitate 1-month and 3-month formulations in the maintenance treatment of schizophrenia: a single-arm, open-label, interventional study in Rwandan healthcare settings. BMJ Open. 2026; 16(6):e109753.  
5 Kuru E, Ozdemir I, Yucens B, et al. Comparison of side effects between 3‐monthly and 1‐monthly paliperidone palmitate formulations in patients with schizophrenia. Hum Psychopharmacol. 2026;41(1):e70033.  
6 Berwaerts J, Liu Y, Gopal S, et al. Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia - a randomized clinical trial. JAMA Psychiatry. 2015;72(8):830-839.  
7 Center for Drug Evaluation and Research. Clinical Pharmacology and Biopharmaceutics Review. NDA 207946 - INVEGA TRINZA (paliperidone palmitate 3-month) - Reference ID: 3748068. 2015- [cited 2024 February 22]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207946Orig1s000ClinPharmR.pdf
8 Cellini L, Donatis DD, Mercolini L, et al. Switch to 3-month long-acting injectable paliperidone may decrease plasma levels. J Clin Psychopharmacol. 2021;41(6):694-696.  

Would you like to clear and leave your conversation? Message history will be lost.